-
Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'
Tuesday, April 17, 2018 - 10:21am | 1124Read More...Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is taking on a broad list of indications with RNAi therapeutics, from bleeding disorders to hypercholesterolemia to amyloidosis. “We’re really building a company that can emerge as a top five biotech company over the next five or so years,...
-
Alnylam Pharmaceutical Surges After Rare Disease Drug Met Key Endpoints
Wednesday, September 20, 2017 - 7:25am | 415Read More...Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) surged higher by more than 20 percent early Wednesday morning after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through...
-
Exclusive: Dicerna CEO Talks Goals For 2017, Competitors And Prospects Under Trump
Wednesday, February 22, 2017 - 2:36pm | 785Read More...Benzinga recently had the opportunity to pick the brain of Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) CEO Douglas M. Fambrough, Ph.D. We first looked into what RNA interference is and how it's used to treat genetic diseases. We then talked products, partnerships and stock performance and...
-
Exclusive: Dicerna CEO Discusses Financials And Institutional Investors
Thursday, February 16, 2017 - 9:40am | 861Read More...Benzinga recently had the chance to chat with Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., who explained what RNA interference is and how it is used to treat genetic diseases. Beyond this theoretical explanation, the exec walked us through the company’s...
-
Exclusive: Dicerna CEO Talks Products, Partnerships And Stock Performance
Wednesday, February 15, 2017 - 1:54pm | 708Read More...Benzinga recently had the chance to chat with Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., who explained what RNA interference (RNAI) is and how it is used to treat genetic diseases. Beyond this theoretical explanation, the exec elaborated on the company...
-
Exclusive: Dicerna CEO Explains RNA Interference And How It's Used To Treat Rare Genetic Diseases
Tuesday, February 14, 2017 - 10:40am | 964Read More...Ever heard of RNA Interference? In case you haven’t, Benzinga reached out to Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., and asked him to explain how it works. Silencing Genes “RNA Interference (RNAI) is a natural process. It is a biological...
-
Maxim Analyst Issues Update On Tekmira's Ebola Research Development
Monday, April 13, 2015 - 8:58am | 290Read More...In a report published Monday, Maxim Group analyst Jason Kolbert commented on Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)'s ongoing research into the Ebola virus. Tekmira is part of an international consortium known as the International Severe Acute Respiratory and Emerging Infection Consortium (...
-
Shares Of Alnylam Pharmaceuticals Lower Following Equity Offering
Wednesday, January 21, 2015 - 10:03am | 109Read More...Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) tumbled 4 percent Wednesday morning as the company priced 4.73 million shares of common stock at $95 per share after announcing on Tuesday it plans to initiate a public offering of common stock. All of the shares being offering will be sold by...
-
Glaucus Research Profiles Tekmira Pharmaceuticals; Shares Down 2%
Monday, November 10, 2014 - 1:22pm | 227Read More...Shares of Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR) were trading lower on Monday after Glaucus Research highlighted a “Strong Sell” recommendation with a $7 to $10 price target. “Tekmira is hugely overvalued and its share price is poised to collapse,” Glaucus...
